Impax Laboratories (IPXL) Initiates Phase III Trial of IPX066 in Parkinson's
More News related to IPXL
- Impax Laboratories Schedules Conference Call for Fourth Quarter and Full Year 2009 Financial Results
- Impax Laboratories (IPXL) Confirms Challenge Initiation of Patents Listed by Daiichi Sankyo's WELCHOL Tablets
- Impax Laboratories Confirms Patent Challenge Relating to WELCHOL(R) 625 mg Tablets
- Notable Analyst Rating Changes 1/8: HAL, AMAT, JCP, AGU, ESV, RDN, More Upgraded; M, KO, STX, ERIC, WEN, PCS, More Downgraded
- Goldman Sachs Downgraded Generics to Neutral; MYL, IPXL Cut to Neutral
More News related to FDA
- AspenBio Pharma (APPY) Reports Results from Interim Analysis for Ongoing Trial of AppyScore
- XenoPort (XNPT) Said FDA Moves PDUFA Date Due to February 11
- Dendreon (DNDN) CEO Says Provenge Salesforce Will Be 125 People, Sees Full Manufacturing Ability by Mid-2011
- U.S. FDA to Become More Stringent on Medical Imaging Equipment (GE, SI)
- BSD Medical (BSDM) Initiates Phase 3 Clinical Study of BSD-2000 Hyperthermia System
Impax Laboratories, Inc. (NASDAQ: IPXL) initiated a multinational Phase III trial of its late-stage drug candidate IPX066 in advanced Parkinson's disease (PD) patients. IPX066 is an investigational extended release carbidopa-levodopa product intended to rapidly achieve and then sustain effective blood concentrations of levodopa, potentially improving PD clinical symptom management.
This is the second of two Phase III studies designed to support marketing approval of IPX066 in Parkinson's disease. Impax Pharmaceuticals previously reported in June the initiation of the first Phase III study of IPX066 in naive PD patients.
Related Categories
FDAStocks Mentioned
+0.02Sign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
